Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 10/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.39 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589039 | 0.88 | CHRM4 (0.36) | CHRM4TPSAB1TPSD1TPSG1AKR1C3 | |
| SCHEMBL345122 | 0.87 | CHRM4 (0.43) | CHRM4TPSAB1TPSD1TPSG1 | |
| SCHEMBL345663 | 0.85 | CHRM4 (0.42) | CHRM4TPSAB1TPSD1TPSG1CHRM2 | |
| SCHEMBL3269077 | 0.82 | CHRM4 (0.49) | CHRM4TPSAB1TPSD1TPSG1SIRT2 | |
| SCHEMBL25384099 | 0.80 | CHRM4 (0.38) | CHRM4AKR1C3CHRM2CPB2PDE10A | |
| SCHEMBL344784 | 0.80 | HRH3 (0.41) | TPSAB1TPSD1TPSG1SIRT2SIRT1 | |
| SCHEMBL345436 | 0.80 | PDE10A (0.40) | CHRM4TPSAB1TPSD1TPSG1SIRT2 | |
| SCHEMBL30589027 | 0.78 | CHRM4 (0.37) | CHRM4CPB2 | |
| SCHEMBL2404169 | 0.78 | CHRM4 (0.45) | CHRM4TPSAB1TPSD1TPSG1AKR1C3 | |
| SCHEMBL21828548 | 0.78 | CPB2 (0.37) | CHRM4CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | CHRM4 1210/4885TPSAB1 4330/4885TPSD1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.